[go: up one dir, main page]

PE20151602A1 - SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 - Google Patents

SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3

Info

Publication number
PE20151602A1
PE20151602A1 PE2015001752A PE2015001752A PE20151602A1 PE 20151602 A1 PE20151602 A1 PE 20151602A1 PE 2015001752 A PE2015001752 A PE 2015001752A PE 2015001752 A PE2015001752 A PE 2015001752A PE 20151602 A1 PE20151602 A1 PE 20151602A1
Authority
PE
Peru
Prior art keywords
hydroxy
amino
methyl
hydroxyquinolin
derivatives
Prior art date
Application number
PE2015001752A
Other languages
English (en)
Inventor
Jane Montserrat Julia
Carrera Francesc Carrera
Quinones Maria Prat
Duran Carlos Puig
Lorenzo Francesca Pajuelo
Andres Juan Antonio Perez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47827112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20151602A1 publication Critical patent/PE20151602A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a sales de adicion cristalinas y farmaceuticamente aceptables de (i) derivados de un acido sulfonico o hidroxicarboxilico o un derivado sulfimida, o un solvato farmaceuticamente aceptable del mismo y (ii) un derivado de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1H)-ona de formula (I); donde: R1 representa un atomo de hidrogeno o un grupo alquilo C1-C4; R2 y R3 independientemente representan un atomo de hidrogeno, un atomo de halogeno, etc; A representa un grupo alquileno C1-C4 opcionalmente sustituido con uno o mas grupos alquilo C1-C2; L representa un enlace directo, un grupo -NH(CO)-, etc. Las sales preferidas son: etanodisulfonato de hidroxi(di-2-tienil)acetato de trans-4-((3-(2-cloro-4-(((2R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino)metil)-5-metoxifenilamino)-3-oxopropil)(metil)amino)-ciclohexilo; disacarinato de 2-hidroxi-2,2-di(tiofen-2-il)acetato de trans-4-((2-(2-cloro-4-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino)-metil)-5-metoxifenilcarbamoiloxi)etil)-(metil)amino)-ciclohexilo, y ; Sal L-tartrato de 2-hidroxi-2,2-di(tiofen-2-il)acetato de trans-4-((2-(2-cloro-4-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino)-metil)-5-metoxifenilcarbamoiloxi)etil)-(metil)amino)ciclohexilo
PE2015001752A 2013-02-27 2014-02-27 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 PE20151602A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382060 2013-02-27
US201361804558P 2013-03-22 2013-03-22

Publications (1)

Publication Number Publication Date
PE20151602A1 true PE20151602A1 (es) 2015-11-04

Family

ID=47827112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001752A PE20151602A1 (es) 2013-02-27 2014-02-27 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3

Country Status (33)

Country Link
US (1) US9562039B2 (es)
EP (1) EP2961407B1 (es)
JP (1) JP6364429B2 (es)
KR (1) KR102002668B1 (es)
CN (1) CN105025897B (es)
AR (2) AR094910A1 (es)
AU (1) AU2014222645B2 (es)
BR (1) BR112015020152B1 (es)
CA (1) CA2901865C (es)
CL (1) CL2015002402A1 (es)
CR (1) CR20150427A (es)
DK (1) DK2961407T3 (es)
DO (1) DOP2015000197A (es)
EA (1) EA028566B1 (es)
ES (1) ES2674085T3 (es)
HR (1) HRP20181097T1 (es)
HU (1) HUE039303T2 (es)
IL (1) IL240278B (es)
LT (1) LT2961407T (es)
MX (2) MX358624B (es)
MY (1) MY180350A (es)
PE (1) PE20151602A1 (es)
PH (1) PH12015501754A1 (es)
PL (1) PL2961407T3 (es)
PT (1) PT2961407T (es)
RS (1) RS57297B1 (es)
SG (1) SG11201505868QA (es)
SI (1) SI2961407T1 (es)
SM (1) SMT201800254T1 (es)
TW (1) TWI643853B (es)
UY (1) UY35355A (es)
WO (1) WO2014131851A1 (es)
ZA (1) ZA201505374B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2948149A4 (en) 2013-01-23 2016-12-14 Aldeyra Therapeutics Inc BY TOXIC ALDEHYDIC DISEASES AND TREATMENT
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
KR102398639B1 (ko) * 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
CN113544121A (zh) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
EP0147475B1 (en) 1983-09-26 1987-03-18 MAGIS FARMACEUTICI S.p.A. Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
WO2001014339A2 (en) 1999-08-20 2001-03-01 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
ES2329133T3 (es) 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2074094A1 (en) 2006-10-04 2009-07-01 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
PT2242759E (pt) 2008-02-06 2012-12-17 Astrazeneca Ab Compostos
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
CN103936716B (zh) 2009-04-23 2016-09-07 施万呼吸有限责任公司 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物
JP5379224B2 (ja) 2009-04-30 2013-12-25 帝人ファーマ株式会社 四級アンモニウム塩化合物
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
EP2386555A1 (en) * 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2718280B1 (en) 2011-06-10 2015-09-16 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
PL3329919T3 (pl) 2011-11-11 2020-05-18 Gilead Apollo, Llc Inhibitory ACC i ich zastosowania
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP6421989B2 (ja) 2012-12-06 2018-11-14 チエシ ファルマスティスィ エス.ピー.エー. ムスカリン受容体アンタゴニストおよびβ2アドレナリン受容体アゴニスト活性を有する化合物
AR093832A1 (es) 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
SI2961407T1 (en) 2018-07-31
CA2901865C (en) 2020-04-21
KR20150123245A (ko) 2015-11-03
TWI643853B (zh) 2018-12-11
EA201500875A1 (ru) 2016-06-30
JP2016510011A (ja) 2016-04-04
CN105025897B (zh) 2018-03-23
EP2961407A1 (en) 2016-01-06
SMT201800254T1 (it) 2018-07-17
MX358624B (es) 2018-08-28
SG11201505868QA (en) 2015-09-29
EA028566B1 (ru) 2017-12-29
AU2014222645A1 (en) 2015-08-13
BR112015020152B1 (pt) 2021-01-26
WO2014131851A1 (en) 2014-09-04
ES2674085T3 (es) 2018-06-27
HRP20181097T1 (hr) 2018-09-07
TW201443043A (zh) 2014-11-16
JP6364429B2 (ja) 2018-07-25
ZA201505374B (en) 2016-07-27
PL2961407T3 (pl) 2018-10-31
AU2014222645B2 (en) 2017-11-30
US20160009698A1 (en) 2016-01-14
HK1212246A1 (en) 2016-06-10
IL240278A0 (en) 2015-09-24
RS57297B1 (sr) 2018-08-31
UY35355A (es) 2014-09-30
BR112015020152A2 (pt) 2017-07-18
US9562039B2 (en) 2017-02-07
HUE039303T2 (hu) 2018-12-28
CL2015002402A1 (es) 2016-01-08
DK2961407T3 (en) 2018-05-28
CR20150427A (es) 2015-11-18
CN105025897A (zh) 2015-11-04
PH12015501754B1 (en) 2015-11-09
KR102002668B1 (ko) 2019-07-23
EP2961407B1 (en) 2018-04-11
IL240278B (en) 2019-08-29
AR094911A1 (es) 2015-09-09
PT2961407T (pt) 2018-05-18
DOP2015000197A (es) 2015-09-30
AR094910A1 (es) 2015-09-09
LT2961407T (lt) 2018-05-10
PH12015501754A1 (en) 2015-11-09
CA2901865A1 (en) 2014-09-04
MY180350A (en) 2020-11-28
MX2015010680A (es) 2017-09-08
MX2015010679A (es) 2016-05-31

Similar Documents

Publication Publication Date Title
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
EA201591537A1 (ru) Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR083813A1 (es) Derivados de pirazol aminopirimidina como moduladores de lrrk2
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
AR097079A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
DOP2014000287A (es) Compuestos de fenoxietil piperidina
MX2014011752A (es) Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
PE20091036A1 (es) Derivado de quinolina como antagonista del receptor p2x7
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
ES2568909T3 (es) Novedosos compuestos antagonistas del receptor de la neuroquinina 1
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
EA201490031A1 (ru) Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth

Legal Events

Date Code Title Description
FC Refusal